Alan Health Review

What Alan Health charges

• Glutathione: $155/mo — per month, and true only on a six-month plan paid upfront — the page's own footnote reads "*Paid upfront with a 6-month plan. Actual price to the consumer will depend on the product and plan purchased"
• NAD+: $235/mo — per month, and true only on a two-month plan paid upfront — the page's own footnote reads "*Paid upfront with a 2-month plan. Actual price will depend on the product and plan purchased", a different commitment from the one under the same seller's glutathione figure
• Sermorelin: $199/mo — per month, and true only on a three-month plan paid upfront — the page's own footnote reads "*Paid upfront with a 3-month plan. Actual price to the consumer will depend on the product and plan purchased"; the figure is displayed as a reduction from a stated former price of $295, and nothing here establishes that $295 was ever charged

Three per-month figures, three different commitments

Each of the three product pages compared here carries a starting figure with a month marker and an asterisk, and each asterisk resolves to a footnote naming a prepayment length. The lengths are six months, two months and three months, one per product.

The footnote is what makes each per-month figure true. Read without it, the three look like comparable monthly rates from one seller; read with it, they are a six-month prepay, a two-month prepay and a three-month prepay.

Every one of these rows carries its own commitment in the qualifier for that reason, and the qualifiers differ from each other on purpose.

Each footnote also says the actual price depends on the product and plan purchased, so the published figure is a floor even inside its own commitment.

The warning letter, and exactly what it says

The federal warning-letter record holds one letter to the company named in this seller's own terms, issued in February 2026 and posted the following month by the compounding-quality office. The address on the letter matches the notice address in the terms, which is what establishes it is the same company rather than a name collision.

The letter says the agency reviewed the website in December 2025 and found compounded weight-loss products whose pictured label identified the brand, suggesting the brand was the compounder when it is not, and that the representations were therefore false or misleading.

That is a labelling and advertising finding about two weight-loss compounds. It is not a quality or contamination finding, it does not say any product was unsafe, and it does not concern the three compounds this site compares this seller on.

Two of the fifty-three sellers compared here carry a published federal warning letter on their row, and this is one of them. On this site a letter is disclosed and never scored: it moves no position on any board.

The company is named; the state footprint is not

The terms name the operating company and its trading names, give a notice address, name the state whose law governs and name a different state for venue. The footer separately names the clinical groups the platform works with.

That is a fuller answer to who is charging you than most sellers here give, and the roles are named separately rather than merged.

On coverage the site says only that certain services are available to individuals located in certain states, and that a user may not access the services from outside a state where its prescribers are licensed. Neither sentence is followed by a list.

Twenty-nine of the fifty-three sellers here publish no state list at all, and this is one of them, so eligibility is settled inside an intake rather than before one.

A former price, a hover menu, and no named pharmacy

One of the three figures is displayed as a reduction from a stated former price. Nothing on the page establishes that the former price was ever charged, and this site makes no claim either way; the qualifier records both numbers.

The site's own navigation menu holds roughly forty more figures that only appear when a hover control is used. That control was not operated, so those figures are unread rather than absent, and nothing on this row is derived from them.

Eleven of the fifty-three sellers here name the facility that fills an order; this is one of the forty-two that do not, which is notable on a seller whose warning letter is about who the compounder is.

No lab work is described as included in any of the three plan figures.

FDA disclosure

Alan Health received an FDA warning letter issued February 2026. A warning letter discloses; it does not, on its own, disqualify a provider — see the trade-offs above for what this one concerned.

How we verified this

• Read each of the three product pages as rendered text in a browser and audited every dollar-bearing element for a laid-out box before recording a figure.
• Read the footnote under each figure separately rather than assuming one footnote covers the page, which is how the three different prepayment lengths were found.
• Left the hover menu unopened and recorded that its figures are unread rather than absent, so nothing on this row rests on them.
• Recorded the struck-through former price beside the reduced figure without asserting that the former price was ever charged.
• Searched the published federal warning-letter record by company name and read the resulting letter in full.
• Matched the recipient address and contact address on the letter against the address in the seller's own terms, rather than relying on a name match.
• Ran the same search for the two clinical groups named in the footer; each returned exactly one unrelated company, which is the shape a false match takes.
• Scoped the letter to what it says: website labelling of two weight-loss compounds, not a quality finding and not about the compounds compared here.
• Censused the terms and four product and catalogue pages for a state list and found none, recording the two sentences that stand in for one.
• Confirmed the host answers a nonsense path with its own not-found page at two path depths in the same pass.
• Re-counted the no-state-list, pharmacy-naming and warning-letter claims against the current roster rather than reusing earlier figures.